In a phase 3 trial, the daily GLP-1 pill has shown "meaningful weight loss" and similar side effects to injectable GLP-1 drugs like Ozempic, Eli Lilly has said., Health, Times Now ...

Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every ...

Chinese drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...

Digestion issues, fatigue, and high costs haven’t stopped some from finding power and transformation through GLP-1 medications.

Search trends reveal India’s wellness market shifting from home remedies to prescription weight-loss drugs, clinical ...

Eli Lilly and Company (NYSE: LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Market OutlineThe Global Weight Loss Drugs Market is valued at USD 2.88 Billion in 2024 and is projected to reach a value ...